GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that a recent study provides new evidence for anti-cirrhotic effects of GFT505 in the context of NASH.
from The Medical News http://ift.tt/1wEBm9e
from The Medical News http://ift.tt/1wEBm9e
No comments:
Post a Comment